Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Departure of Directors or Certain Officers
5 Apr 24
8-K
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
6 Mar 24
8-K
Other Events
23 Jan 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Other Events
5 Jan 24
8-K
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
2 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Sep 23
8-K
Other Events
16 Aug 23
8-K
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
3 Aug 23
8-K
Departure of Directors or Certain Officers
13 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
6 Mar 24
424B5
Prospectus supplement for primary offering
3 Aug 23
424B5
Prospectus supplement for primary offering
9 Jun 23
424B5
Prospectus supplement for primary offering
8 Jun 23
S-8
Registration of securities for employees
9 Mar 23
424B5
Prospectus supplement for primary offering
4 Aug 22
S-3/A
Shelf registration (amended)
2 Aug 22
S-3
Shelf registration
1 Jul 22
S-8
Registration of securities for employees
3 Mar 22
424B1
Prospectus with pricing info
25 Jun 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
Other
EFFECT
Notice of effectiveness
5 Aug 22
CORRESP
Correspondence with SEC
2 Aug 22
UPLOAD
Letter from SEC
6 Jul 22
EFFECT
Notice of effectiveness
25 Jun 21
CERT
Certification of approval for exchange listing
24 Jun 21
CORRESP
Correspondence with SEC
24 Jun 21
SEC STAFF
SEC staff action: Order
24 Jun 21
CORRESP
Correspondence with SEC
24 Jun 21
UPLOAD
Letter from SEC
23 Jun 21
CORRESP
Correspondence with SEC
23 Jun 21
Ownership
SC 13G
Frazier Life Sciences Public Fund, L.P.
9 Apr 24
4
Joseph J Ferra Jr
19 Mar 24
4
Alan B. Sandler
4 Mar 24
4
Julie M Cherrington
4 Mar 24
3
Alan B. Sandler
4 Mar 24
3
Julie M Cherrington
4 Mar 24
4
Valerie Malyvanh Jansen
20 Feb 24
4
Tammy Furlong
20 Feb 24
4
David Dornan
20 Feb 24
4
Joseph J Ferra Jr
20 Feb 24